Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-31. Numbers and descriptions here follow the published literature rather than marketing material.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Neanderthals manufactured Middle Palaeolithic stone tools, and are associated with the Mousterian industry, specifically the Levallois technique. After developing this technology from the Acheulean industry, there is a 150,000 year stagnation in Neanderthal stone tool innovation. Stalled technological growth may have followed from their low population, impeding complex ideas from being spread across their range or passed down generationally. Neanderthals normally collected raw materials from a nearby source, no more than 5 km (3.1 mi). Some communities were also making tools from shells and bone. They may have hafted tips onto spears using birch bark tar. European populations had also been manufacturing wood spears, namely the 400,000 year old British Clacton Spear; 300,000 year old German Schöningen spears; and 120,000 year old German Lehringen Spear, including both likely thrown (Schöningen) and thrusting (Lehringen) types. It has been suggested that Neanderthals likely specifically selected particular wood types (such as European yew in the case of the Clacton and Lehringen spears) for manufacturing spears for their beneficial material properties. Neanderthals invented the earliest dry distillation process to produce birch tar, a substance with adhesive and medicinal properties. A complex underground apparatus was used to distill birch tar from masses of bark, which suggests that a high degree of cultural innovation and evolution took place in the European Middle Paleolithic period.
Large hardened nuclear weapon storage areas were built across European countries in anticipation of local US and European forces falling back as the conventional NATO defense from the Soviet Union, named REFORGER, was believed to only be capable of stalling the Soviets for a short time.
CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders. NORD - National Organization for Rare Disorders (NORD) is an American national non-profit patient advocacy organization that is dedicated to individuals with rare diseases and the organizations that serve them. EURODIS - Rare Diseases Europe (EURODIS) is a unique, non-profit alliance of over 700 rare disease patient organizations across Europe that work together to improve the lives of the 30 million people living with a rare disease in Europe.
The amino acids that make up a particular helix can be plotted on a helical wheel, a representation that illustrates the orientations of the constituent amino acids (see the article for leucine zipper for such a diagram). Often in globular proteins, as well as in specialized structures such as coiled-coils and leucine zippers, an α-helix will exhibit two "faces" – one containing predominantly hydrophobic amino acids oriented toward the interior of the protein, in the hydrophobic core, and one containing predominantly polar amino acids oriented toward the solvent-exposed surface of the protein. Changes in binding orientation also occur for facially-organized oligopeptides. This pattern is especially common in antimicrobial peptides, and many models have been devised to describe how this relates to their function. Common to many of them is that the hydrophobic face of the antimicrobial peptide forms pores in the plasma membrane after associating with the fatty chains at the membrane core.
Sources: en.wikipedia.org
=== Fission product === In contrast to the rare natural occurrence, bulk quantities of technetium-99 are produced each year from spent nuclear fuel rods, which contain various fission products. The fission of a gram of uranium-235 in nuclear reactors yields 27 mg of technetium-99, giving technetium a fission product yield of 6.1%. Other fissile isotopes produce similar yields of technetium, such as 4.9% from uranium-233 and 6.21% from plutonium-239. An estimated 49,000 TBq (78 metric tons) of technetium was produced in nuclear reactors between 1983 and 1994, by far the dominant source of terrestrial technetium. Only a fraction of the production is used commercially. Technetium-99 is produced by the nuclear fission of both uranium-235 and plutonium-239. It is therefore present in radioactive waste and in the nuclear fallout of fission bomb explosions. Its decay, measured in becquerels per amount of spent fuel, is the dominant contributor to nuclear waste radioactivity after about 104–106 years after the creation of the nuclear waste. From 1945 to 1994, an estimated 160 TBq (about 250 kg) of technetium-99 was released into the environment during atmospheric nuclear tests. The amount of technetium-99 from nuclear reactors released into the environment up to 1986 is on the order of 1000 TBq (about 1600 kg), primarily by nuclear fuel reprocessing; most of this was discharged into the sea.
1 by the Secretary of State for Home Affairs 2 by the London County Council 1 by the Corporation of the City of London 2 (jointly) by the councils of the metropolitan boroughs of the County of London 1 (jointly) by the county councils of Buckinghamshire, Essex, Hertfordshire, Middlesex 1 (jointly) by the county councils of Kent and Surrey 1 (jointly) by the corporations of the county boroughs of Croydon, East Ham, West Ham 1 representative of the Metropolitan Police, appointed by the Secretary of State for Home Affairs 1 representative of the City of London Police appointed by the City Corporation 1 appointed by the Minister of Transport The members of the committee were to appoint a chairman themselves.
The predecessor of the Parliament of South Africa, before the 1910 Union of South Africa, was the bicameral Parliament of the Cape of Good Hope. This was composed of the House of Assembly (the lower house) and the Legislative Council (the upper house). This predecessor dated back to the beginnings of Cape independence in 1853 and was elected according to the multi-racial Cape Qualified Franchise system, whereby suffrage qualifications were applied equally to all males, regardless of race. The buildings of the Cape Parliament went on to house the Parliament of South Africa, after union.
Sources: en.wikipedia.org
== Functions == GIP initially derived its name from its inhibitory effect on stomach acid secretion, its ability to protect the small intestine from acid-induced damage, its slowing of the pace with which consumed foods exit the stomach, and its reduction of general gastrointestinal motility. However, the initially hypothesized mechanism was incorrect, as it was later discovered that the hormone achieved its effects only when its concentration exceeded basal physiologic levels and that it operated similarly to secretin. It is now believed that GIP primarily acts as an inducer of insulin secretion, which is stimulated primarily by hyperosmolarity of glucose in the duodenum. Since its mechanism was uncovered in 1995, the hormone has sometimes been referred to as glucose-dependent insulinotropic peptide, while retaining the acronym GIP. The amount of insulin secreted is greater when glucose is administered orally than intravenously. In addition to its role as an incretin, GIP is known to inhibit apoptosis of pancreatic beta cells and to promote their proliferation. It also stimulates glucagon secretion and fat accumulation. GIP receptors are expressed in many organs and tissues including those of the central nervous system, enabling regulation of appetite and satiety. As of 2013, GIP was believed to be an important driver of bone remodeling. Researchers at the Universities of Angers and Ulster noted that genetic ablation of the GIP receptor in mice resulted in profound alterations of bone microarchitecture through modification of the adipokine network.
=== North Atlantic === Recipes for fish maw, specifically codfish maw, are documented in Hannah Glasse's 1747 English cuisine cookbook The Art of Cookery Made Plain and Easy: fish maw is presented in gravy, broiled, and as a fricassee. Cod maw was later described as a 'delicacy' in the 1911 American food industry encyclopedia, The Grocer's Encyclopedia, by Artemas Ward. Cod maw is a traditional food of Newfoundland, owing to the ubiquity of the cod fishing industry. It was typically salted for preservation until use, then boiled and stewed. The popularity of cod maw dropped in the late 20th century along with cod tongue and cheeks, but has begun to see a resurgence with culinary tourism and interest in nose to tail eating. In Portugal, Codfish maw (Portuguese: sames) was salted and brought to shore to be eaten as a fisherman's dish. Portuguese sailors from Figueira da Foz would rely on codfish maw as a byproduct of cod fishing in Newfoundland. Feijoada is traditionally made with fish maw instead of pork in Figueira da Foz (Feijoada de sames).
=== Diagnosis of a syndesmotic injury === Diagnosis of syndesmosis injuries by physical examination is often straightforward. Physical examination findings that are often positive include the squeeze test and the external rotation test. Patients with high-grade syndesmosis injuries often cannot perform a single-leg heel raise. Patients report pain in varying degrees over the anterior and often posterior distal fibular joint.
Besides OI's association with sensorineural hearing loss, OI is associated with several neurological abnormalities, usually involving the central nervous system, due to deformities in the skeletal structures surrounding it. Neurological complications, especially basilar invagination, may adversely affect life expectancy. In OI, this is most often due to upwards migration of the dens, a feature of the C2 vertebra. Neurosurgery may be needed to correct severe abnormalities when they risk the patient's life or cause either great suffering or intolerable neurological deficits.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.